Developer docs
API playgroundTry for free, no card

Search company profiles

GenVivo

Full company profile

uuid0005l5f

Namestring
GenVivo
Legal namestring
GenVivo, Inc.
Websiteurl
genvivoinc.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

GenVivo is a private, clinical-stage biopharmaceutical company developing off-the-shelf gene therapy immunotherapies for cancer treatment. The company is built around its proprietary G-Volve platform, a non-integrating retroviral vector system that delivers dual therapeutic payloads (a prodrug-activated suicide gene HSV-eTK combined with immunostimulatory cytokines) via intravenous administration, designed to generate immune effectors in vivo without requiring ex vivo cell processing or genomic integration.

The company's pipeline includes four candidates: lead asset GEN2 (encoding HSV-eTK and GM-CSF), currently in a US Phase 1/1b trial (NCT06391918) for advanced solid tumors following 48-patient Phase 1 testing in Asia; GEN-1013 (HSV-eTK + IL-12), in preclinical development with IND filing planned for mid-2026; GEN-1018 (immuno-gene therapy); and GEN-310 (in vivo CAR-T/NK vector for B-cell malignancies), currently in IND-enabling stage. GenVivo targets oncology patients with advanced or refractory solid tumors and hematologic malignancies, with clinical investigation conducted at cancer centers including City of Hope National Medical Center.

The business model is pre-revenue and pre-commercial, with GenVivo generating no product sales. Anticipated future revenue will derive from commercialization of its gene immunotherapy pipeline candidates subject to regulatory approval. The company historically operated a vertically-integrated model with in-house cGMP manufacturing, clinical operations, and R&D; however, the Southern California manufacturing facility was closed in February 2026, with assets auctioned via Tiger Group. GenVivo is headquartered in San Marino, California, employs 11-50 people, and is privately-held with founder/owner-operated ownership and no disclosed institutional investor backing in available sources.

Short descriptiontext

GenVivo is a private clinical-stage biopharmaceutical company developing off-the-shelf, non-integrating retroviral gene therapy immunotherapies for advanced solid tumors and B-cell malignancies, with lead candidate GEN2 in Phase 1/1b clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Marino, United States
HQ citystring
San Marino
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer gene therapy, non-integrating viral vectors, cancer immunotherapy, clinical stage biopharma, in vivo CAR-T
Industry4 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Gene Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Product Revenue (Future)
TypeOne Time License
Description

GenVivo is a pre-revenue, clinical-stage private biopharmaceutical company. Its primary anticipated revenue stream will derive from the commercialization of its oncology gene immunotherapy pipeline candidates (GEN2, GEN-1013, GEN-310), once regulatory approval is obtained. The company maintains vertically integrated cGMP manufacturing capabilities in-house.

genvivoinc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GenVivo is a clinical-stage biopharmaceutical company developing off-the-shelf, intravenously administered gene vector immunotherapies for cancer. Its lead candidate GEN2 combines HSV-eTK and GM-CSF in a non-replicating retroviral vector and is in Phase 1/2 clinical trials (NCT06391918) for advanced solid tumors. Pipeline candidates GEN-1013, GEN-310, and GEN-1018 extend the approach to IL-12 delivery and in vivo CAR-T/NK generation for B-cell malignancies, all built on the proprietary G-Volve non-integrating retroviral vector platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • GEN2 was well-tolerated with minimal toxicity and no dose-dependent Treatment Emergent Adverse Events (TEAEs) across a 1000-fold dose range in 48 patients; no toxicity-defined Maximum Tolerated Dose (MTD) was identified
+3 more records
Product overview1 text field

GenVivo is a clinical-stage biopharmaceutical company developing an off-the-shelf vector platform for cancer gene medicine immunotherapies. The company's portfolio includes multiple product candidates: GEN2 (HSV-eTK/GM-CSF retroviral vector in Phase 1/2 clinical trial for solid tumors), GEN-1013 (IL-12 encoding vector in preclinical development with IND filing planned mid-2026), GEN-310 (in vivo CAR-T/NK vector for B cell malignancies in IND-enabling stage), and GEN-1018. These are built on the proprietary G-Volve non-integrating retroviral vector platform technology that enables systemic administration of therapeutic genes without genome integration. The company maintains fully integrated in-house capabilities including cGMP manufacturing, process development, and clinical operations.

Product and service2 records
1GEN2
CategoryCancer Gene Therapy Product Candidate
Description

Non-replicating mRNA retroviral gene therapy vector encoding HSV-eTK and GM-CSF, administered intravenously with valganciclovir prodrug to kill tumors and stimulate patient-specific immune responses; in Phase 1/2 trial for advanced solid tumors.

2GEN-1013
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-27
Description

City of Hope National Medical Center in Duarte, CA serves as a key clinical trial site for GenVivo's GEN2 Phase 1/1b clinical trial (NCT06391918). Dr. Daneng Li, Associate Professor and Hepatobiliary Lead and Co-Director of the Neuroendocrine Tumor Program at City of Hope, is a co-investigator and provided commentary on the trial initiation. The partnership enables GenVivo to conduct clinical investigation of its GEN2 gene vector immunotherapy in patients with advanced solid tumors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenVivo

Cancer Gene Immunotherapygenvivoinc.com

GenVivo is a private clinical-stage biopharmaceutical company developing off-the-shelf, non-integrating retroviral gene therapy immunotherapies for advanced solid tumors and B-cell malignancies, with lead candidate GEN2 in Phase 1/1b clinical trials.

What GenVivo does

GenVivo is a private, clinical-stage biopharmaceutical company developing off-the-shelf gene therapy immunotherapies for cancer treatment. The company is built around its proprietary G-Volve platform, a non-integrating retroviral vector system that delivers dual therapeutic payloads (a prodrug-activated suicide gene HSV-eTK combined with immunostimulatory cytokines) via intravenous administration, designed to generate immune effectors in vivo without requiring ex vivo cell processing or genomic integration.

The company's pipeline includes four candidates: lead asset GEN2 (encoding HSV-eTK and GM-CSF), currently in a US Phase 1/1b trial (NCT06391918) for advanced solid tumors following 48-patient Phase 1 testing in Asia; GEN-1013 (HSV-eTK + IL-12), in preclinical development with IND filing planned for mid-2026; GEN-1018 (immuno-gene therapy); and GEN-310 (in vivo CAR-T/NK vector for B-cell malignancies), currently in IND-enabling stage. GenVivo targets oncology patients with advanced or refractory solid tumors and hematologic malignancies, with clinical investigation conducted at cancer centers including City of Hope National Medical Center.

The business model is pre-revenue and pre-commercial, with GenVivo generating no product sales. Anticipated future revenue will derive from commercialization of its gene immunotherapy pipeline candidates subject to regulatory approval. The company historically operated a vertically-integrated model with in-house cGMP manufacturing, clinical operations, and R&D; however, the Southern California manufacturing facility was closed in February 2026, with assets auctioned via Tiger Group. GenVivo is headquartered in San Marino, California, employs 11-50 people, and is privately-held with founder/owner-operated ownership and no disclosed institutional investor backing in available sources.

GenVivo firmographics

Firmographics
Name
GenVivo
Legal name
GenVivo, Inc.
Website
https://genvivoinc.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
GenVivo is a private clinical-stage biopharmaceutical company developing off-the-shelf, non-integrating retroviral gene therapy immunotherapies for advanced solid tumors and B-cell malignancies, with lead candidate GEN2 in Phase 1/1b clinical trials.
Ownership category
akta.pro rank

GenVivo industry classification

Industry
Product category
Cancer Gene Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cancer gene therapy
  • Non-integrating viral vectors
  • Cancer immunotherapy
  • Clinical stage biopharma
  • In vivo CAR-T

Where GenVivo is headquartered

Location

Headquarters

HQ city
San Marino
HQ country
United States
HQ region
North America

Offices2 records

Markets served

GenVivo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Product Revenue (Future): GenVivo is a pre-revenue, clinical-stage private biopharmaceutical company. Its primary anticipated revenue stream will derive from the commercialization of its oncology gene immunotherapy pipeline candidates (GEN2, GEN-1013, GEN-310), once regulatory approval is obtained. The company maintains vertically integrated cGMP manufacturing capabilities in-house.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

GenVivo product offering

Product offering

Core offering

GenVivo is a clinical-stage biopharmaceutical company developing off-the-shelf, intravenously administered gene vector immunotherapies for cancer. Its lead candidate GEN2 combines HSV-eTK and GM-CSF in a non-replicating retroviral vector and is in Phase 1/2 clinical trials (NCT06391918) for advanced solid tumors. Pipeline candidates GEN-1013, GEN-310, and GEN-1018 extend the approach to IL-12 delivery and in vivo CAR-T/NK generation for B-cell malignancies, all built on the proprietary G-Volve non-integrating retroviral vector platform.

Product overview

GenVivo is a clinical-stage biopharmaceutical company developing an off-the-shelf vector platform for cancer gene medicine immunotherapies. The company's portfolio includes multiple product candidates: GEN2 (HSV-eTK/GM-CSF retroviral vector in Phase 1/2 clinical trial for solid tumors), GEN-1013 (IL-12 encoding vector in preclinical development with IND filing planned mid-2026), GEN-310 (in vivo CAR-T/NK vector for B cell malignancies in IND-enabling stage), and GEN-1018. These are built on the proprietary G-Volve non-integrating retroviral vector platform technology that enables systemic administration of therapeutic genes without genome integration. The company maintains fully integrated in-house capabilities including cGMP manufacturing, process development, and clinical operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • GEN2 Non-replicating mRNA retroviral gene therapy vector encoding HSV-eTK and GM-CSF, administered intravenously with valganciclovir prodrug to kill tumors and stimulate patient-specific immune responses; in Phase 1/2 trial for advanced solid tumors.
  • GEN-1013

Quantifiable outcome

  • GEN2 was well-tolerated with minimal toxicity and no dose-dependent Treatment Emergent Adverse Events (TEAEs) across a 1000-fold dose range in 48 patients; no toxicity-defined Maximum Tolerated Dose (MTD) was identified
  • +3 more outcomes

Companies that use GenVivo

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

GenVivo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

GenVivo partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • City of Hope National Medical CentercoreStrategic or Co-development Partner · 27 June 2024City of Hope National Medical Center in Duarte, CA serves as a key clinical trial site for GenVivo's GEN2 Phase 1/1b clinical trial (NCT06391918). Dr. Daneng Li, Associate Professor and Hepatobiliary Lead and Co-Director of the Neuroendocrine Tumor Program at City of Hope, is a co-investigator and provided commentary on the trial initiation. The partnership enables GenVivo to conduct clinical investigation of its GEN2 gene vector immunotherapy in patients with advanced solid tumors.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

GenVivo competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

GenVivo social profiles

Digital presence

GenVivo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenVivo leadership team

Management profile

Number of profiles

Profiles12 records

GenVivo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenVivo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenVivo

What does GenVivo do?

GenVivo is a clinical-stage biopharmaceutical company developing off-the-shelf, intravenously administered gene vector immunotherapies for cancer. Its lead candidate GEN2 combines HSV-eTK and GM-CSF in a non-replicating retroviral vector and is in Phase 1/2 clinical trials (NCT06391918) for advanced solid tumors. Pipeline candidates GEN-1013, GEN-310, and GEN-1018 extend the approach to IL-12 delivery and in vivo CAR-T/NK generation for B-cell malignancies, all built on the proprietary G-Volve non-integrating retroviral vector platform.

Is GenVivo a public or private company?

GenVivo is a private company. It is classified as family owned and is currently operating.

When was GenVivo founded?

GenVivo was founded in 2023. It employs 11 to 50 people.

Where is GenVivo based?

GenVivo is headquartered in San Marino, United States, in the North America region.

How does GenVivo make money?

One revenue line is on record: gene Therapy Product Revenue (Future).

Does GenVivo have an API?

No public API is recorded for GenVivo.

What industry is GenVivo in?

GenVivo's product category is Cancer Gene Immunotherapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTiger Group Offers New & Late-Model GMP Biopharma Manufacturing and QC Laboratory Equipment and Inventory in Online AuctionTiger Group announced an online auction opening February 11 for new and late-model GMP biopharma manufacturing and QC laboratory equipment from GenVivo's facility closure in Southern California, with bidding closing on February 18. The auction features assets with an original at-cost value exceeding $5 million, including manufacturing skids, bioreactors, chromatography systems, and brand-new support inventory such as single-use bags, filters, and sterile supplies. The equipment comes from top manufacturers including Sartorius, Thermo Fisher, Sepragen, Bio-Rad, and others.YahooTiger Group Offers New & Late-Model GMP Biopharma Manufacturing and QC Laboratory Equipment and Inventory in Online AuctionTiger Group is hosting an online auction of biopharma manufacturing and QC laboratory equipment from GenVivo's facility in Southern California, starting February 11, 2026. The assets include new and late-model equipment with an original value exceeding $5 million, aimed at industries from small labs to large pharma companies.GlobeNewswireGenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual MeetingGenVivo presented Phase 1 clinical trial results for GEN2, an off-the-shelf systemic cancer immunotherapy, at the 2025 SITC Annual Meeting, demonstrating the therapy was well-tolerated with no dose-limiting toxicity across 23 patients with advanced solid tumors. The trial showed dose-dependent increases in immunocytokines and vector persistence confirming the therapy's mechanism of action, with stable disease observed beyond 24 weeks. The company indicated these findings provide clinical validation for the G-Volve vector platform and support advancement of additional pipeline programs including IL-12 and in vivo CAR-T vectors.